RESCLAR 250mg/5ml price in UAE

Overview

Welcome to Dwaey, specifically on RESCLAR 250mg/5ml Suspension/Powder for page.
This medicine contains an important and useful components, as it consists of Clarithromycin.
RESCLAR 250mg/5ml is available in the market in concentration 250mg/5ml and in the form of Suspension/Powder for.

NEOPHARMA is the producer of RESCLAR 250mg/5ml and it is imported from UAE, The most popular alternatives of RESCLAR 250mg/5ml are listed downward .

Mode Of Action

Clarithromycin inhibits protein synthesis by binding to 50s ribosomal subunits of susceptible organisms. It has activity against susceptible streptococci and staphylococci as well as other species including B. catarrhalis, L. spp, C. trachomatis and U. urealyticum.

Indication

Respiratory tract infections
Skin and soft tissue infections
Leprosy
peptic ulcer disease
pharyngitis
tonsillitis
acute maxillary sinusitis
acute bacterial exacerbation of chronic bronchitis
pneumonia
legionellosis
Helicobacter pylori
lyme disease
Community-Acquired Pneumonia.

Precaution

Renal and hepatic impairment; macrolide cross-resistance; lactation, children. Lactation: Drug is excreted in breast milk; use with caution

Side Effects

>10% Gastrointestinal (GI) effects
general (13%) 1-10% Abnormal taste (adults
3-7%)
Diarrhea (3-6%)
Nausea (adults
3-6%)
Vomiting (adults
1%; children
6%)
Elevated blood urea nitrogen (BUN; 4%)
Abdominal pain (adults
2%; children
3%)
Rash (children
3%)
Dyspepsia (2%)
Heartburn (adults
2%)
Headache (2%)
Elevated prothrombin time (PT; 1%) <1% Anaphylaxis
Anorexia
Anxiety
Clostridium difficile colitis
Dizziness
Dyspnea
Elevated liver function tests
Glossitis
Hallucinations
Hepatic dysfunction
Hepatitis
Hypoglycemia
Increased alkaline phosphatase
Increased aspartate aminotransferase
Increased bilirubin
Increased serum creatinine
Jaundice
Leukopenia
Manic behavior
Neuromuscular blockade
Neutropenia
Pancreatitis
Psychosis
QT prolongation
Seizures
Stevens-Johnson syndrome
Thrombocytopenia Potentially Fatal: Pseudomembranous colitis
anaphylaxis
Stevens-Johnson syndrome.

Contra indication

Hypersensitivity. Patients receiving terfenadine, astemizole, pimozide, cisapride and ergot derivatives. Pregnancy; history of acute porphyria.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam). Potentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.